• linkedin
  • Increase Font
  • Sharebar

    Targeted biopsy: High-risk PCa detection rises 30%

    Targeted magnetic resonance imaging/ultrasound fusion prostate biopsy increases detection of high-risk prostate cancers and decreases detection of low-risk cancers compared with standard ultrasound-guided biopsy, according to new findings from a large-scale National Institutes of Health study.

    The study was published in JAMA (2015; 313:390-7).

    RELATED: MRI guiding future of prostate Ca diagnosis

    Researchers reported that 30% more high-risk prostate cancers were diagnosed with targeted fusion-guided biopsy than with standard biopsy. In addition, 17% fewer low-risk cancers were diagnosed with the fusion-guided approach.

    "This study demonstrates that targeted fusion-guided biopsy could significantly enhance our ability to identify patients with high-risk prostate cancers that need more aggressive treatment," said lead author Mohummad Minhaj Siddiqui, MD, of the University of Maryland School of Medicine, Baltimore in a news release from that institution. Dr. Siddiqui was a fellow at the NIH when the study was conducted.

    "With fusion technology, we now have a tool to help us differentiate high-risk cancers from low-risk ones that may require minimal or no treatment," he added. "There is a concern that we over-diagnose and over-treat low-risk cancers that are unlikely to be terminal, and this technology enables us to make a more reliable diagnosis than the current standard practice."

    Dr. Siddiqui also added a note of caution: "While these findings could translate into substantial benefit to patients, this study is preliminary with regard to clinical endpoints such as recurrence of disease and prostate cancer-specific mortality," he said, noting that randomized clinical trials will be needed to determine the impact of targeted biopsy on clinical outcomes.

    The study of 1,003 men was conducted at the NIH from 2007 to 2014, with Peter A. Pinto, MD, serving as the senior investigator. Participants were referred for biopsy because of elevated PSA or an abnormal digital rectal exam. They received targeted and concurrent standard biopsies.

    Next: 30% more high-risk cancers diagnosed with targeted Bx

    More on Prostate Cancer

    Analysis uncovers thousands of potential cancer markers

    MRI-targeted prostate biopsy offers four fundamental benefits

    Medicare to cover another prostate Ca test


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available